title: A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS C020-CUPIC)• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results• Futility Rules in Telaprevir Combination Treatment• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim ResultsPLUS Meeting Abstract Summaries With Expert Commentary by: Jean-Pierre Bronowicki, MD, PhDDepartment of Hépato-GastroenterologieCentre Hospitalier Universitaire de Nancy-BraboisVandoeuvre-lès-Nancy, France.